- Patent Title: Blood glucose control system with carbohydrate therapy indication
-
Application No.: US17062022Application Date: 2020-10-02
-
Publication No.: US11040141B2Publication Date: 2021-06-22
- Inventor: Firas H. El-Khatib , Edward R. Damiano
- Applicant: BETA BIONICS, INC.
- Applicant Address: US MA Concord
- Assignee: BETA BIONICS, INC.
- Current Assignee: BETA BIONICS, INC.
- Current Assignee Address: US MA Concord
- Agency: Knobbe Martens Olson & Bear, LLP
- Main IPC: A61M5/172
- IPC: A61M5/172 ; G16H20/17 ; G16H10/40 ; G16H40/67 ; A61M5/142 ; G16H20/60

Abstract:
A blood glucose control system can generate an indication of total carbohydrate therapy over a period during use by a subject. The system can be connected to a medicament pump configured to deliver insulin therapy, other types of medicament therapy, or a combination of medicament therapies to the subject. The system can determine an amount of a counter-regulatory agent to respond to an impending risk of hypoglycemia or an episode of hypoglycemia and determine a dose of carbohydrate therapy based at least in part on the amount of the counter-regulatory agent. The system can track determined doses of carbohydrate therapy to generate the indication of total carbohydrate therapy over the period.
Public/Granted literature
- US20210016006A1 BLOOD GLUCOSE CONTROL SYSTEM WITH CARBOHYDRATE THERAPY INDICATION Public/Granted day:2021-01-21
Information query
IPC分类: